title: Irinotecan for children with relapsed solid tumors.
abstract: Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.
authors.affiliation: Department of Hematology/Oncology, Gunma Children's Medical Center, Seta-gun, Gunma, Japan. shitara@gcmc.pref.gunma.jp
authors.forename: Toshiji
authors.initials: T
authors.lastname: Shitara
authors.forename: Akira
authors.initials: A
authors.lastname: Shimada
authors.forename: Ryoji
authors.initials: R
authors.lastname: Hanada
authors.forename: Tadashi
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Keisei
authors.initials: K
authors.lastname: Kawa
authors.forename: Hideo
authors.initials: H
authors.lastname: Mugishima
authors.forename: Tohru
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Mimaya
authors.forename: Atsushi
authors.initials: A
authors.lastname: Manabe
authors.forename: Masahito
authors.initials: M
authors.lastname: Tsurusawa
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Tsuchida
mesh_terms: D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D000077146:Irinotecan; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D012008:Recurrence; D012074:Remission Induction; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D047368:Tumor Burden / Q000187:drug effects; D009396:Wilms Tumor / Q000188:drug therapy
chemical_list: D000077146:Irinotecan; D002166:Camptothecin